Study suggested that constant use of Semaglutide may be linked to development of a condition called non-arteritic ischemic optic neuropathy.

After reports claimed that filings in patent offices in India, the US, and Europe did not mention ICMR or its scientists, but only BBIL and its scientists, the Hyderabad-based biotechnology (biotech) company clarified that in the "rush" to develop vaccines and file appropriate patents, BBIL had missed adding ICMR's name in the original filings.

Auto manufacturers have focused on launching CNG variants of their popular models to meet consumer demand for vehicles with lower running costs.

'There is not any negative connotation associated with it.'

'That is a significant milestone for us and something we aspired for.'

India currently does not have any XBB 1.5 variant-based vaccines available.

India has covered enough population with vaccine and infection, but protein vaccines should remain available on payment basis for elderly and those with comorbidities.

Automotive (auto) major Mahindra & Mahindra (M&M), which is readying to launch nine sport utility vehicles (internal combustion engine/ICE), seven Born Electric Vehicles (BEVs), and seven light commercial vehicles by 2030, has outlined an investment of Rs 27,000 crore in its auto business between 2024-25 (FY25) and 2026-27 (FY27). Over the next three years, the company will deploy Rs 37,000 crore, including its auto business, farm business (Rs 5,000 crore), and service business (Rs 5,000 crore).

Maintaining the balance of gut microbiota is important as an imbalance, also known as dysbiosis, can cause or aggravate different diseases, including but not limited to digestive problems such as inflammatory bowel syndrome, mental health issues like anxiety and depression and menstrual problems.

Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA). In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus. CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.

Nearly one in two luxury cars sold in India in the first three months of 2024 was a Mercedes Benz, which achieved its best ever quarter (January-March), selling 5,412 units, up 15 per cent year-on-year (Y-o-Y) from 4,697 units in the previous year.

The government has been stringent with pricing changes. Prices of 651 essential medicines came down from April 1, 2023 by 6.73 per cent with the government capping ceiling prices of these drugs.

'Every hospital now tracks length of stay closely.' 'More efficiency is brought into the system now.'

Indian pharma companies are focussing on flagship products or mother brands under which they launch various new combinations to ensure robust revenue growth as well as therapy leadership. An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales. Sheetal Sapale, vice-president, commercial at Pharmarack, said, "Mother brands are analogous to an aggressive player who has put in a lot of effort during the prime years of life but now continues to silently nurture the brand family to collectively cross newer benchmarks of success."

koda Auto India is set to drive in a new car by the first half of next year to reach its target of 100,000 unit annual sales in the country by 2026. The compact sports utility vehicle (SUV) will be positioned against the likes of Maruti Brezza, Hyundai Venue, and Kia Sonet, and would be competitively priced, a senior company official said. koda will also export the car to right-hand-drive markets like Australia, New Zealand and the Asean nations.

For the consumer, there would be practically no impact on prices of essential medicines this year.

The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.

'Now that we are a pure-play India business, many investors are open to investing.'

Delhi-headquartered Fortis Healthcare is open to acquisition of hospitals with over 250-300 bed sizes as part of its strategy to grow at a faster clip. It may also opt for a neutral brand name soon. Neutral brand is a new brand, which is not owned by any of the stakeholders.

The Indian pharmaceutical market (IPM) grew 6.8 per cent to touch a turnover of ~1.93 trillion in calendar year 2023, despite volumes going down marginally by 0.9 per cent. This indicates the price increase has been the major growth driver. Growth in the moving annual turnover (the previous 12 months' turnover) in December was 5.1 per cent and that in new product introduction 2.6 per cent, while volumes dipped 0.9 per cent, leading to an overall growth rate of 6.8 per cent, according to the data from market research firm Pharmatrac.